VERTEX PHARMACEUTICALS INC / MA Inventory, Raw Materials, Net of Reserves
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Inventory, Raw Materials, Net of Reserves of $233.00 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative
us-gaap:InventoryRawMaterialsNetOfReserves · last filed 2026-08-04
- 2026-06-30: Inventory, Raw Materials, Net of Reserves $233.00M.
- 2026-03-31: Inventory, Raw Materials, Net of Reserves $267.40M.
- 2025-12-31: Inventory, Raw Materials, Net of Reserves $259.80M.
- 2025-09-30: Inventory, Raw Materials, Net of Reserves $278.60M.
| Period end | Inventory, Raw Materials, Net of Reserves | Inventory, Raw Materials, Net of Reserves as first filed |
|---|---|---|
| 2026-06-30 | $233.00M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $267.40M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $259.80M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $278.60M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $221.40M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $250.50M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $252.00M 10-K · filed 2026-02-13 | |
| 2024-09-30 | $141.10M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $112.10M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $95.70M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $78.70M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $77.50M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $71.80M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $58.10M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $38.10M 10-K · filed 2024-02-15 | |
| 2022-09-30 | $32.20M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $30.40M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $42.20M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $42.40M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $45.99M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $47.74M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $44.92M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $46.20M 10-K · filed 2022-02-09 | $46.23M 10-K · filed 2021-02-11 |
| 2020-09-30 | $42.54M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $30.16M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $24.84M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $26.25M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $21.29M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $12.96M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $11.65M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $9.68M 10-K · filed 2020-02-13 | |
| 2018-09-30 | $13.73M 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $16.12M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $17.59M 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $20.92M 10-K · filed 2019-02-13 | |
| 2017-09-30 | $12.68M 10-Q · filed 2017-10-30 | |
| 2017-06-30 | $13.88M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $9.17M 10-Q · filed 2017-04-28 | |
| 2016-12-31 | $6.35M 10-K · filed 2018-02-15 | |
| 2016-09-30 | $9.82M 10-Q · filed 2016-10-31 | |
| 2016-06-30 | $5.41M 10-Q · filed 2016-08-01 | |
| 2016-03-31 | $9.94M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | $8.70M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $8.67M 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $8.15M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $7.83M 10-Q · filed 2015-05-04 | |
| 2014-12-31 | $8.51M 10-K · filed 2016-02-16 | |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $0.00 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-05 | |
| 2013-12-31 | $489.00K 10-K · filed 2015-02-13 | |
| 2013-09-30 | $232.00K 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $3.10M 10-Q · filed 2013-08-02 | |
| 2013-03-31 | $4.80M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $3.75M 10-K · filed 2014-02-11 | |
| 2012-09-30 | $4.51M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $5.08M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $28.51M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $32.21M 10-K · filed 2013-03-01 | |
| 2011-09-30 | $20.10M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $21.77M 10-Q · filed 2011-08-09 | |
| 2011-03-31 | $7.82M 10-Q · filed 2011-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |